Biohaven Says In RESILIENT SMA Study, Taldefgrobep Alfa Showed Clinically Meaningful Improvements In Motor Function At All Timepoints On The Motor Function Measurement-32 Scale, But The Treatment Arm Did Not Statistically Separate On The Primary...
Biohaven Says In RESILIENT SMA Study, Taldefgrobep Alfa Showed Clinically Meaningful Improvements In Motor Function At All Timepoints On The Motor Function Measurement-32 Scale, But The Treatment Arm Did Not Statistically Separate On The Primary...
biohaven在RESILIENt SMA研究中表示，Taldefgrobep alfa在運動功能測量-32量表的所有時間點上顯示出臨床意義的運動功能改善，但治療組在主要指標上沒有統計學上的分離...
Biohaven Says In RESILIENT SMA Study, Taldefgrobep Alfa Showed Clinically Meaningful Improvements In Motor Function At All Timepoints On The Motor Function Measurement-32 Scale, But The Treatment Arm Did Not Statistically Separate On The Primary Outcome At Week 48 Compared To The Placebo+Standard Of Care Group
熱門市場機會
熱門討論
中概股財報季火熱：驚喜盈利能否延續漲勢？
1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？
Moomoo News Global
03/04 23:26
中國兩會：會議前後股票價格變動的關鍵要點
熱門討論
FOMC維持利率但不確定性高企：美股後市走向如何？
🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？
Moo Live
03/20 02:25
聯邦公開市場委員會新聞發佈會，2025年3月19日